



Contact: Cliff Glickman  
Tel: (434) 525-8225  
Cliff Glickman Corporate Communications

## **Dr. Anthony Senagore, Leading Clinical Surgeon, Joins AeroSurgical**

Chair of Colorectal Surgery at University of Southern California agrees to become Chief Medical Officer of Pioneering Surgical Device Company.

Dr. Anthony Senagore, a highly regarded surgeon who is currently Chief of Colon and Rectal Surgery at the University of Southern California-Keck School of Medicine, has agreed to become the Chief Medical Officer for AeroSurgical Limited, a medical device company. AeroSurgical is developing products to improve clinical outcomes through the use of its proprietary, state-of-the-art aerosol platform to deliver therapeutics to patients during laparoscopic surgery.

Dr. Senagore will retain his post at the University of Southern California while assuming the role of Chief Medical Officer for AeroSurgical. "I believe that AeroSurgical has the potential to make a dramatic impact on laparoscopic practice and improve clinical outcomes," Senagore said. "I am delighted to be a part of the organization."

Dr. Senagore will be responsible for designing and overseeing the company's clinical strategy. "Dr. Senagore is an extremely talented surgeon who also has substantial clinical trial experience," said Nevan Elam, AeroSurgical's President and Chief Executive Officer. "He will be an important part of making sure that our product candidates achieve their clinical endpoints."

Before joining the University of Southern California, Dr. Senagore was the Chief Academic Officer for Spectrum Health and Professor of Surgery at Michigan State University and prior to that he was the Krause-Lieberman Chair in laparoscopic colorectal surgery at The Cleveland Clinic and medical director in the Office of Medical Operations in Cleveland, Ohio. He has published over 150 articles and edited three textbooks.

Last month, Dr. Jane Shaw, a long-time pharmaceutical executive and current director of Intel and McKesson, joined AeroSurgical's board of directors.

AeroSurgical's lead product candidate, AeroSurge PR1, is designed to deliver local anesthetics into the abdominal cavity during laparoscopic surgery to effectively eliminate post-operative pain as well as achieve earlier ambulation, a reduction in opiate use and shorten hospital stays for non-ambulatory procedures. The company is also working on a formulation of a therapeutic to be delivered through its aerosol platform to address the problem of surgical adhesions. AeroSurgical has offices in the San Francisco Bay Area and Galway, Ireland.

**Ireland**  
AeroSurgical Ltd.  
Galway Business Park  
Dangan  
Galway

**United States**  
AeroSurgical Ltd.  
2995 Woodside Road  
Suite 400  
Woodside, CA 94062

Registration No. 452525  
VAT No. IE 9739190H

**Email:** [info@aerosurgical.com](mailto:info@aerosurgical.com)  
**Web:** [www.aerosurgical.com](http://www.aerosurgical.com)

**Phone:** +353 91 540450

**Phone:** +1 650 530 0032